©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 28, 2015; 21(36): 10327-10335
Published online Sep 28, 2015. doi: 10.3748/wjg.v21.i36.10327
Published online Sep 28, 2015. doi: 10.3748/wjg.v21.i36.10327
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system
Kichang Han, Jin Hyoung Kim, Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul 138-736, South Korea
Author contributions: Kim JH designed the study, outlined the draft, and supervised the project; and Han K carried out the literature search and wrote the manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest to report.
Correspondence to: Jin Hyoung Kim, MD, Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Poongnap-2dong, Songpa-gu, Seoul 138-736, South Korea. jhkimrad@amc.seoul.kr
Telephone: +82-2-30104384 Fax: +82-2-4760090
Received: April 23, 2015
Peer-review started: April 24, 2015
First decision: May 18, 2015
Revised: June 11, 2015
Accepted: August 30, 2015
Article in press: August 31, 2015
Published online: September 28, 2015
Processing time: 158 Days and 4.3 Hours
Peer-review started: April 24, 2015
First decision: May 18, 2015
Revised: June 11, 2015
Accepted: August 30, 2015
Article in press: August 31, 2015
Published online: September 28, 2015
Processing time: 158 Days and 4.3 Hours
Core Tip
Core tip: This article describes the role of transarterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC) according to the barcelona clinic liver cancer (BCLC) staging system. Notably, TACE is the treatment of choice in the treatment of intermediate HCC (BCLC stage B). However, in clinical practice, TACE has been used as an alternative or combination therapy in patients with early or advanced HCC. Therefore, diverse treatment modalities, including TACE, should be considered for the best interests of patients with HCC.